Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03929250 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacokinetics of Centella Asiatica in the Elderly
A Early Phase 1 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT03929250: Completed Early Phase 1 study, sponsored by Oregon Health and Science University.
NCT03929250 is a Early Phase 1 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 8 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03929250, a Early Phase 1 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will measure the oral bioavailability and pharmacokinetics of known bioactive compounds from a standardized Centella asiatica water extract (CAW) product (CAP) in cognitively healthy elders.
Primary Outcome
Following oral administration of a product made from a water extract of Centella asiatica (CAP), the plasma concentration of Centella asiatica derived bioactive compounds (triterpenes, caffeoylquinic acids, and their metabolites) will be measured in blood samples obtained over a 12 hour period, using high performance liquid chromatography tandem mass spectrometry in order to generate a pharmacokinetic curve, and determine pharmacokinetic parameters (maximum concentration and area under the curve
Interventions
- DRUG 2g Centella asiatica water extract product
- DRUG 4g Centella asiatica water extract product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-07-05 |
| Est. Completion | 2024-01-03 |
| Phase | Early Phase 1 |
What the finished NCT03929250 record still lists
NCT03929250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which 2g Centella asiatica water extract product is the first listed.
NCT03929250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03929250 about?
NCT03929250 is a clinical study titled "Pharmacokinetics of Centella Asiatica in the Elderly". This study will measure the oral bioavailability and pharmacokinetics of known bioactive compounds from a standardized Centella asiatica water extract (CAW) product (CAP) in cognitively healthy elders.
What is the current status of trial NCT03929250?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2019-07-05. Estimated completion is 2024-01-03.
What interventions are being tested in trial NCT03929250?
The interventions under investigation include: 2g Centella asiatica water extract product (DRUG), 4g Centella asiatica water extract product (DRUG).
Who is sponsoring clinical trial NCT03929250?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03929250's enrollment target sits among peer trials
8 1782nd of 2000 higher than 176 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI